These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27245012)

  • 1. [To explore evidence evaluation for harm: establishing the body of evidence for harm for postmarketing traditional Chinese medicine].
    Liao X; Xie YM; Wang YY; Nicola R
    Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4723-7. PubMed ID: 27245012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Explore method about post-marketing safety re-evaluation of Chinese patent medicines based on HIS database in real world].
    Yang W; Xie Y; Zhuang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2779-82. PubMed ID: 22292363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluating the Body of Evidence on Postmarketing Clinical Safety of Chinese Herbs].
    Liao X; Xie YM
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2017 Jan; 37(1):109-114. PubMed ID: 30695435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. To establish a body of evidence on safety for postmarketing Chinese medicine: A new research paradigm.
    Liao X; Xie YM; Robinson N; Wang YY
    Chin J Integr Med; 2017 Mar; 23(3):226-232. PubMed ID: 27900605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sample size calculation in clinical post-marketing evaluation of traditional Chinese medicine].
    Fu Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2904-6. PubMed ID: 22292397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Discussion on development of four diagnostic information scale for clinical re-evaluation of postmarketing herbs].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Dec; 36(24):3548-50. PubMed ID: 22368876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Construction and realization of real world integrated data warehouse from HIS on re-evaluation of post-maketing traditional Chinese medicine].
    Zhuang Y; Xie B; Weng S; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2883-7. PubMed ID: 22292392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical orientation and thought on several problems in post-marketed reassessment of traditional Chinese medicine].
    Wang X; Su X; Yu J; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2893-7. PubMed ID: 22292394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Designs and thoughts of real world integrated data warehouse from HIS on re-evaluation of post-maketing traditional Chinese medicine].
    Zhuang Y; Xie B; Weng S; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2880-2. PubMed ID: 22292391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on method on post-marketing traditonal Chinese medicine safety assessment].
    Kou Q; Zhao S; Feng G; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Basic requirements on post-marketing clinical re-evaluation of chinese medicine and phase IV clinical trials].
    Xie Y; Wang Y; Tian F; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2764-7. PubMed ID: 22292359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phase 0 clinical trials and post-marketed re-evaluation of clinical safety in injection of traditional Chinese medicine].
    Wei X; Zhang Z; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2874-6. PubMed ID: 22292389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Research about re-evaluation of screening of traditonal Chinese medicine symptoms item of post-marketing medicine Xuezhikang].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2898-900. PubMed ID: 22292395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thought on several problems of post-marketing herbs clinical evaluation in special populations].
    Zhou A; Lian F
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2776-8. PubMed ID: 22292362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Design requirements for clinical trials on re-evaluation of safety and efficacy of post-marketed Chinese herbs].
    Xie Y; Wei X
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2768-70. PubMed ID: 22292360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of nested case-control study on safe evaluation of post-marketing traditional Chinese medicine injection].
    Xiao Y; Zhao Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2796-8. PubMed ID: 22292368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thinking on risk assessment and risk management of post-marketing Chinese medicine].
    Yu X; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(2):262-4. PubMed ID: 22737865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological approaches to developing and establishing the body of evidence on post-marketing Chinese medicine safety.
    Liao X; Robinson N
    Chin J Integr Med; 2013 Jul; 19(7):494-7. PubMed ID: 23818200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Process and key points of clinical literature evaluation of post-marketing traditional Chinese medicine].
    Liu H; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2848-50. PubMed ID: 22292382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Guidance of FDA risk evaluation and mitigation strategy and enlightenment to drug risk management of post-marketing Chinese medicine].
    Li Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2825-7. PubMed ID: 22292376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.